121 patents
Page 6 of 7
Utility
Method of treatment
18 May 20
Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
Christian Lavedan, Mihael H. Polymeropoulos
Filed: 5 Dec 18
Utility
Benzisoxazoles
29 Apr 20
The present invention relates to novel fatty acid esters of the reversible Iloperidone metabolite P-88-8991, their preparation, their use as pharmaceuticals and pharmaceutical compositions containing them.
Joachim Nozulak, Hans Kalkman
Filed: 25 Dec 19
Utility
Treatment of circadian rhythm disorders
6 Apr 20
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 4 Nov 18
Utility
Method of treatment
6 Apr 20
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions.
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Filed: 18 Jul 19
Utility
Highly purified pharmaceutical grade tasimelteon
6 Apr 20
A process for preparing a batch of highly purified, pharmaceutical grade tasimelteon comprises analyzing a batch of tasimelteon synthesized under GMP conditions for the presence of one or more identified impurities.
Deepak Phadke, Natalie M. Platt, Ravi K. Pandrapragada
Filed: 5 Sep 18
Utility
Use of Tradipitant In Motion Sickness
1 Apr 20
Disclosed herein is a method of treating or preventing motion sickness or at least one symptom thereof, comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos
Filed: 2 Oct 19
Utility
Genetic Markers for Enhancing Efficacy of Antipsychotic Treatment with Iloperidone
4 Mar 20
The present invention relates to the selection of patients with enhanced antipsychotic treatment efficacy with iloperidone based on a patient's genotype at one or more single nucleotide polymorphism (SNP) loci and to treatment of such patients based upon the identification of their genetic information.
Mihael H. Polymeropoulos, Sandra Smieszek
Filed: 15 Aug 19
Utility
Method of predicting a predisposition to QT prolongation
24 Feb 20
The present invention describes an association between genetic polymorphisms in the BAI3 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Christian Lavedan, Simona Volpi, Louis Licamele
Filed: 13 Sep 17
Utility
Method of predicting a predisposition to QT prolongation
24 Feb 20
The present invention describes an association between genetic polymorphisms in the ceramide kinase-like (CERKL) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Christian Lavedan, Simona Volpi, Louis Licamele, Kendra Tomino Mack, Callie Michelle Heaton
Filed: 17 Apr 18
Utility
Method of predicting a predisposition to QT prolongation
17 Feb 20
The present invention describes an association between genetic polymorphisms in the FAM13A1 (family with sequence similarity 13, member A1) gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Christian Lavedan, Simona Volpi, Louis Licamele
Filed: 13 Sep 17
Utility
Method of treatment based on polymorphisms of the KCNQ1 gene
17 Feb 20
The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Curt D. Wolfgang, Mihael H. Polymeropoulos
Filed: 13 Sep 17
Utility
Method of predicting a predisposition to QT prolongation
17 Feb 20
The present invention describes an association between genetic polymorphisms in the ABCC2 gene and a predisposition to prolongation of the QT interval, and provides related methods for the prediction of such a predisposition, the administration of QT interval-prolonging compounds to individuals having such a predisposition, and determining whether a compound is capable of inducing QT prolongation.
Christian Lavedan, Simona Volpi, Louis Licamele
Filed: 17 Sep 17
Utility
Method of Treatment with Tradipitant
29 Jan 20
Disclosed herein is a method of treatment of gastric motility disorders and of improving gastric motility comprising treatment with the NK-1 receptor antagonist, tradipitant.
Mihael H. Polymeropoulos, Gunther Birznieks
Filed: 30 Sep 19
Utility
Multiple Myeloma Treatment
8 Jan 20
The invention relates generally to the treatment of multiple myeloma.
Mihael H. Polymeropoulos, Louis William Licamele, Christian Lavedan
Filed: 25 Aug 19
Utility
Treatment of Circadian Rhythm Disorders
8 Jan 20
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 13 Sep 19
Utility
Iloperidone for the Treatment of Schizophrenia
25 Dec 19
Aspects of the invention relate generally to the treatment of schizophrenia in an individual and, more specifically, to the treatment of an individual with iloperidone, an iloperidone metabolite, or a pharmaceutically-acceptable salt thereof.
Mihael H. Polymeropoulos, Curt D. Wolfgang
Filed: 5 Sep 19
Utility
Methods for the Administration of Iloperidone
27 Nov 19
The present invention relates to methods for the identification of genetic polymorphisms that may be associated with a risk for QT prolongation after treatment with iloperidone and related methods of administering iloperidone to patients with such polymorphisms.
Curt Wolfgang, Mihael Polymeropoulos, Christian Lavedan, Simona Volpi
Filed: 7 May 19
Utility
Method of Treatment
6 Nov 19
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions.
Marlene Michelle Dressman, Mihael H. Polymeropoulos, Paolo Baroldi
Filed: 18 Jul 19
Utility
Method of treatment with tradipitant
4 Nov 19
This application relates to a method of treatment with tradipitant, and more particularly, to a method of treatment of pruritus with tradipitant.
Mihael H. Polymeropoulos, Louis William Licamele
Filed: 3 Mar 16
Utility
Treatment of circadian rhythm disorders
21 Oct 19
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Marlene Michelle Dressman, Louis William Licamele, Mihael H. Polymeropoulos
Filed: 25 Nov 17